CI
Cingulate Inc.
CING · NASDAQ
$4.76 +0.21% (+$0.01)
1M -6.67%
Market Cap $64.0M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$3.65
23.3% downside
Current Price
$4.76
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CING is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
71 /100
Cheap P/B 2.73x
EV/EBITDA N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 13.54%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
2 /100
Poor ROA 0.09%
Asset turnover 0.00x
ROIC 2.00%
Debt
70 /100
Low Current ratio 3,500.01x
Int. coverage 20.69x
Net debt/EBITDA -139.79x
Stability
19 /100
Unstable EPS volatility 565.01%
Profitable years 0
Beta -0.89x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CING
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Shane J. Schaffer
Employees
14
Headquarters
Kansas City
Upcoming events
12 NOV
Earnings
Upcoming earnings report